🇺🇸

US SEC Filing Intelligence

· daily

US SEC Filings Daily Market Digest — March 18, 2026

Across 50 SEC filings for March 18, 2026, overarching themes include mixed financial results in 10-Ks with revenue growth in standout performers like TSS Inc (+66% YoY to $245.7M) and Bob's Discount Furniture (+16.8% YoY to $2.37B), contrasted by declines in Harte Hanks (-13.9% YoY) and persistent losses in microcaps like NRHI (net loss +6% YoY to $30.6K, zero cash). M&A activity dominates with proxy supplements for Heritage Commerce/CVB Financial (shareholder meetings March 26) and Two Harbors/UWM due to litigation risks, while capital allocation shows buybacks (TSS 988 shares, XOMA $16M, News Corp $1B program) and dividends (Heartland quarterly). Period-over-period trends reveal improving net losses in Stardust Power (-34% YoY) and XOMA (to $31.7M profit from loss), but margin compression in Bob's (-110 bps to 45.7%) and expense surges in Vyome (+790% op ex). Sector patterns highlight banking M&A hurdles, AI/tech growth (TSS backlog $115M), and pharma pipeline advances amid auditor switches (Tonix to PwC). Forward catalysts cluster in Q2 2026 (XOMA volixibat data) with IPO/ETF launches (Farlong $16M, Morgan Stanley Bitcoin). Implications favor selective longs in growth outliers amid broad small-cap weakness and litigation overhangs.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 18, 2026

Across 50 SEC filings from S&P 500 Consumer Discretionary and related streams, overarching themes include modest revenue growth in retail (e.g., Five Below +22.9% YoY, Bob's Discount +16.8% YoY, Home Depot +3.2% YoY) offset by widespread margin compression (e.g., Bob's gross margin -110 bps to 45.7%, Home Depot ROIC -570 bps to 25.7%) and mixed profitability trends, with 7/12 key financial reporters showing net income improvements averaging +45% YoY but operating losses in high-growth names like HeartFlow (-$117M). Capital allocation leans toward debt expansions (Hilton RCF extension, Hyperfine $40M facility) and M&A (RocketFuel asset sale, FingerMotion Telforge acquisition), signaling liquidity management amid volatility. Forward-looking guidance is optimistic in retail (Five Below FY26 sales $5.20-5.30B, comp +3-5%) but cautious on cash burn (Hyperfine $26-28M). Portfolio-level patterns reveal 6/10 retail filings with comp sales acceleration (avg +10% YoY) but inventory builds (Home Depot +10%, Bob's +15%) hinting demand risks. Neutral sentiment dominates (28/50 filings), with positive financing/M&A catalysts and proxy season ramp-up offering near-term volatility. Critical implications: Favor high-comp growth like Five Below over decelerating giants like Home Depot; monitor Q1 FY26 guidance for margin recovery.

30 high priority 20 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 18, 2026

Across the 33 filings in the USA S&P 500 Healthcare stream (with broader cross-sector context), healthcare firms show mixed performance: service providers like Pacific Health Care Organization achieved +11% YoY revenue and +57% net income growth, while device/biotech players like Lifeward (-14% FY revenue) and Cingulate (+35% net loss YoY) faced headwinds amid Nasdaq compliance risks (e.g., CalciMedica) and funding needs (Artelo Biosciences bridge notes). Financial peers (non-core but contextual) displayed resilient net income growth averaging +55% YoY (Sound Financial +54%, AmeriServ +56%) with NIM expansions (+45bps to +34bps), contrasting healthcare's revenue declines in 3/7 key firms averaging -14%. Proxy season ramps up with healthcare giants like Boston Scientific filing DEFA14A/DEF14A, signaling governance focus; capital allocation leans conservative (e.g., First Financial $0.56 dividend). Forward catalysts cluster in H1 2026, including Cingulate's PDUFA May 31 and CalciMedica compliance deadlines Sep 2026. Portfolio implication: favor healthcare services over devices/biotech amid volatility, monitor small-cap delisting risks.

18 high priority 15 medium 33 total filings
· daily

Global High-Priority Regulatory Events — March 18, 2026

Across 50 filings in the Global High Priority Market Events stream (US SEC focus, March 18, 2026), dominant themes include heightened regulatory scrutiny with 7+ Indian-listed firms facing SEBI/BSE/NSE fines for delayed financials (totaling ~₹30L+), active M&A/takeover landscape via open offers and mergers (e.g., Nilachal Refractories, Heritage Commerce), and mixed financial performances in 10-Ks showing revenue surges in winners like TSS Inc (+66% YoY to $245.7M) offset by widening losses (e.g., dMY Squared -2145% YoY net loss). Period-over-period trends reveal strong growth outliers (avg +40% YoY revenue in consumer/industrials like Bob's Discount +16.8%, Magnum Ice Cream +4.2% organic) but margin compression (Bob's -110 bps gross) and zero-cash shells (Natural Resource Holdings). Capital allocation leans conservative with minor buybacks (TSS 988 shares) and upcoming dividends (ICICI, TVS), while forward-looking catalysts cluster around April board meetings and March 26 shareholder votes. Portfolio-level patterns flag India regulatory risks, SPAC/merger momentum, and AI/consumer growth amid ABS servicing stability. Critical implications: Monitor M&A for takeover premiums, avoid fine-hit microcaps, chase growth outliers pre-earnings.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 18, 2026

The single S-4 filing in the IPO Pipeline stream highlights a high-materiality (9/10) SPAC merger to form Pubco, a digital asset treasury company with primary XRP exposure, backed by over $1B in equity commitments at $10.00 per share and initial holdings of at least 473M XRP from Ripple and sponsors. Mixed sentiment stems from strong structural support like Up-C tax efficiency, six-month lockups on key shares, and a fairness opinion from CCM, offset by risks such as high SPAC redemptions potentially dropping cash below the $5M closing minimum and minority positioning for existing SPAC shareholders. No period-over-period financial trends are disclosed in the filing, but the transaction implies robust pre-merger capital inflows versus typical SPAC dilutions. Leadership by CEO Asheesh Birla and Ripple advisors signals conviction in XRP yield generation and ecosystem strategies. This positions Pubco as a rare public vehicle for concentrated XRP exposure amid crypto market volatility, with implications for IPO-like liquidity in digital assets. Portfolio-level theme: Resurgent SPAC activity targeting niche crypto treasuries despite redemption pressures.

1 high priority 1 total filings
· daily

US Earnings Financial Results SEC Filings — March 18, 2026

Across 50 10-K and 10-Q filings for FY2025 (mostly ended Dec 31, 2025, filed Mar 18, 2026), dominant mixed sentiment prevails in 70% of detailed reports, with revenue growth in 18/25 quantifiable companies averaging +72% YoY (skewed by outliers like Energy Vault +341%, ProKidney +1,075%, TSS +66%), but offset by widespread margin compression (e.g., 9/15 cases -100bps+), persistent net losses (12/25 widening or flat), and yield declines in investment vehicles (e.g., Unknown #1 9.9% from 11.2%, PGIM 9.88% from 11.11%). Retailers like Home Depot (+3.2% sales) and Best Buy (+0.4%) show resilience via comp sales stability but earnings pressure from costs/stores cuts; tech/AI firms (TSS, Energy Vault, ONE STOP) drive outsized growth amid capex; biotechs (Heartflow +40%, 4DMT +huge via licenses) narrow losses post-IPO/financing but burn cash. Capital allocation leans to financings/debt (e.g., Bob's $337M new LT debt, Accelerant $1.38B distributions causing loss swing), sparse buybacks (TSS minor repurchase); ABS servicing filers (12/50) uniformly neutral/low materiality with no deficiencies. Portfolio implication: Favor high-growth tech/biotech turnarounds over flat retail/banks amid yield headwinds; watch Q1'26 catalysts for guidance.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 18, 2026

Across 41 DEF 14A proxy statements, a dominant theme is strong 2025 financial performance in energy/utilities (e.g., Vistra's $5.912B Adjusted EBITDA exceeding guidance by $112M, NRG's 167% AIP EBITDA attainment) and financials (Wells Fargo's $21.3B net income, 12.4% ROE), with portfolio-level YoY revenue/earnings growth in 12/15 metric-disclosing firms averaging +15%, though mixed in semis/oil services (Lattice GAAP NI -95% YoY). Capital returns shine with $1.6B+ repurchases/dividends in multiple (NRG $1.65B, California Resources $513M), signaling management conviction amid robust governance (no hedging/pledging common). Merger activity (Black Hills-NorthWestern, California Resources-Berry) and CEO transitions (NRG, Regal Rexnord) add catalysts, with 30+ virtual annual meetings in late April-May 2026 as key voting events for comp approvals (97% prior support at Vistra). Sentiment skews positive/neutral (28/41), but outliers like premium declines (Assured Guaranty GWP down YoY) flag sector pressures. Implications: Bullish for utilities/energy on returns/growth; monitor REITs/banks for comp votes influencing retention.

41 high priority 41 total filings
· daily

US Executive Officer Management Changes SEC — March 18, 2026

Across 33 SEC filings on US executive and director changes from March 18, 2026, the dominant theme is high turnover with 18 appointments (CFOs, COOs, directors) and 15 departures/retirements, signaling proactive board refreshes in consumer (Coty) and energy sectors but potential instability in biotech (Hepion CEO resignation) and tech (SoundHound CFO exit). Sentiment skews neutral (20/33) with positive tones in 9 cases driven by experienced hires (e.g., Seadrill's Samir Ali, Waste Connections' Daniel Florness), while mixed in growth stories like Accelerant (24% YoY Q4 premium growth to $1.09B but $1.345B FY loss). Period-over-period data sparse but highlights Accelerant's outlier EBITDA surge 149% FY to $282M amid CFO change; no broad margin compression but continuity awards (Eagle $1.175M cash) flag CEO transitions. Portfolio-level patterns show CFO churn in 7 firms (40% small/mid-caps), board expansions in infra/healthcare, and comp-heavy inducements (LifeMD 675K RSUs). Implications: bullish for stable transitions with growth guidance (Accelerant Q1 EBITDA $64-66M), bearish for sudden exits amid suspensions (Graphjet); investors should monitor Q1 earnings for post-change execution.

33 high priority 33 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 18, 2026

Across 31 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is aggressive liquidity pursuits through debt facilities, equity issuances, note extensions, and credit amendments, with 18 companies (58%) announcing new/expanded financing amid potential distress signals like Nasdaq delisting notices in 2 cases and dilutive convertible notes in 5. Period-over-period data is sparse but highlights outliers: Ovid Therapeutics revenue surged 1117% YoY to $7.3M with opex down 20% to $49.7M and net loss halved to $17.4M, contrasting minimal quantitative trends elsewhere. Positive catalysts include M&A (e.g., Independent Bank's $70.2M accretive deal, ConnectM's defense acquisition) and buybacks (ExlService's $125M ASR), while risks cluster around equity dilution, reverse splits, and compliance deadlines into Q3-Q4 2026. Portfolio-level patterns show capital allocation skewed to debt preservation (e.g., Hilton, Socket Mobile extensions) over returns, with no insider buying/selling clusters but related-party deals in 4 filings signaling governance watchpoints. Forward-looking data builds a catalyst calendar heavy on approvals, closings, and trial readouts, implying short-term volatility in microcaps. Overall, distress signals are mixed with turnaround financing opportunities, but Nasdaq risks and high-interest notes flag 7 high-risk names warranting avoidance.

31 high priority 31 total filings
· daily

US SEC Trading Suspension Halt Orders — March 18, 2026

Both CalciMedica, Inc. (CALC) and Glimpse Group, Inc. (GGRP) received Nasdaq deficiency notices on March 13-16, 2026, primarily for failing the minimum bid price requirement (closing below $1.00/share for 30 consecutive business days), with CALC additionally cited for MVLS below $35M, stockholders' equity, and net income standards under Rules 5550(b)(1)/(3). No period-over-period financial trends are detailed in filings, but implied weak performance (low MVLS/equity/net income) signals deteriorating fundamentals amid small-cap pressures. Trading remains uninterrupted for both, providing 180 calendar days to regain compliance by September 9-14, 2026, via measures like reverse stock splits, though success is uncertain. Negative sentiment across filings (materiality 9/10) underscores heightened delisting risks, with no reported insider activity, capital allocation changes, or forward guidance to counter bearish outlook. Portfolio-level pattern: 2/2 companies in Nasdaq Capital Market face simultaneous compliance threats, highlighting microcap vulnerability in biotech (CALC) and emerging tech (GGRP) sectors. Implications include potential volatility from reverse splits or delistings, urging avoidance or short strategies.

2 high priority 2 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 18, 2026

Across 33 US SEC filings on board room changes from March 18, 2026, the dominant theme is high executive turnover, particularly CFOs and controllers (10+ cases including New ERA, McCormick, LifeMD, Accelerant, SoundHound, Cyber Enviro-Tech, MPLX), with 60% involving appointments of experienced internals/externals signaling stability amid growth pushes. Positive sentiment prevails in 30% of filings (e.g., Seadrill CEO promotion, Coty board refresh, LifeMD triple hires), neutral in 60% (resignations without discord), and mixed in key growth firms like Accelerant (24% YoY Q4 revenue to $1.09B but $1.345B FY loss) and SoundHound (8x revenue growth under departing CFO). Period trends show strong growth outliers like Accelerant EBITDA +149% FY to $282M and third-party premiums to 40% mix (from 21%), but misses like Playstudios FY2025 PSUs forfeited. Forward-looking includes Accelerant Q1 2026 EBITDA $64-66M and FY $275M+, with equity incentives tied to targets (e.g., VisionWave $100M revenue milestone). Capital allocation leans to retention via RSUs/PSUs (e.g., Eagle Bancorp $1.175M cash + RSUs, Playstudios new PSUs post-forfeit). Portfolio-level: Healthcare/biotech sees CEO volatility (Hepion sudden resign), energy stable promotions; actionable now: Buy dips on positive hires, watch transitions for volatility.

33 high priority 33 total filings
· daily

US Merger & Acquisition SEC Filings — March 18, 2026

The 13 filings reveal robust M&A and SPAC activity centered on business combinations, extensions, and niche sector acquisitions, with 10/13 involving SPACs showing persistence amid challenges like high redemptions (Voyager: 25.2M shares redeemed, trust at $885k) and one termination (Quartzsea due to CSRC delays). Positive divestitures and acquisitions dominate non-SPAC activity: TriMas $1.45B Aerospace sale yields $1.2B for growth/buybacks; BlockchAIn completes combo with $22.9M rev/$5.7M NI data center targeting AI expansions 2026-27; cannabis M&A surges via Grown Rogue (60% cost savings, Q2 2026 ops) and Global Asset (license options). No period-over-period declines reported across filings (e.g., BlockchAIn 2024 metrics strong, TriMas no quantitative drops); forward looks cluster in Q2-Q4 2026 for operations/expansions. Portfolio trends: Neutral routine SPAC mechanics (unit separations in 2, extensions in 3) mask bullish niche growth in AI/HPC, cannabis, packaging; bearish regulatory hurdles in PRC-related deals. Implications: Capital recycling fuels buybacks/acquisitions; monitor SPAC closings for dilution risks, alpha in post-combo trading (e.g., AIB ticker).

13 high priority 13 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 18, 2026

Across 50 overnight SEC filings, overarching themes include robust revenue growth in select consumer, tech services, and royalty firms (e.g., TSS +66% YoY, Bob's Discount +16.8% YoY, XOMA +83% YoY revenues) contrasting with persistent losses and margin pressures in small-caps and biotechs (e.g., NRHI net loss +2-6% YoY, Harte Hanks revenues -13.9% FY). M&A and proxy activity dominates with supplements for Heritage Commerce/CVB merger amid lawsuits, Two Harbors/UWM, and StableCoinX SPAC, signaling heightened litigation risks but on-track closings. Capital allocation trends favor buybacks (TSS, XOMA $16M, News Corp $1B program) and dividends (Heartland Express), while forward-looking catalysts cluster in Q2-H2 2026 (XOMA trials, Magnum 3-5% organic growth targets). Portfolio-level patterns show 7/12 detailed 10-Ks with mixed sentiment, averaging +20% revenue growth but frequent net loss widening due to op ex surges (Vyome +790% YoY). Sector outliers include strong consumer recovery (Bob's comp sales +7.7%) and ETF launches (Morgan Stanley Bitcoin Trust). Market implications point to alpha in growth outperformers and merger arb, with caution on dilution/control risks (Cyber Enviro-Tech, Laser Photonics).

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 17, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (with broader equity exposure), mixed financial results dominate, with 12/50 showing YoY revenue growth averaging +25% driven by acquisitions (e.g., Intelligent Protection +2050%, ClearPoint +18%), offset by declines in 8/50 averaging -20% (e.g., Telesat -26.8%, Skkynet -34%). Margin compression is evident in 7/15 detailed financials (avg -200 bps, e.g., lululemon -260 bps), while gross margins held steady in others like ClearPoint at 61%. Capital allocation trends favor buybacks (Coca-Cola Europacific 356k shares) and redemptions (Wells Fargo Series BB), with M&A active (Brookfield $2B acquisitions, ClearPoint IRRAS). Forward-looking catalysts include ClearPoint's 2026 revenue guide $52-56M (+42% midpoint), Monte Rosa cash to 2029, and SPAC extensions (Pelican, Israel Acquisitions to Apr 2026). Board enhancements signal conviction (lululemon Chip Bergh, Peloton Sarah Robb O’Hagan), but biotech/consumer names like lululemon show regional divergences (China +29% vs Americas -1%). Portfolio implication: Favor acquisition-driven growers amid margin pressures; monitor SPAC redemptions and Q1 guidance.

33 high priority 17 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 17, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (March 17, 2026), dominant themes include accelerating bank M&A with regulatory approvals for UBFO/CWBC and Mechanics/HomeStreet mergers driving asset/deposit growth (e.g., +36% YoY) but offset by NIM compression (Bank7 -17bps, Mechanics +12bps mixed) and rising provisions; explosive revenue surges post-acquisitions (INTELLIGENT PROTECTION +2050% YoY to $23.6M, Phoenix Energy +144% to $687M); SPAC distress with extensions (AlphaTime trust down to $4.8M from heavy redemptions) and LOIs for financing. Period-over-period trends reveal mixed revenue growth (8/20 financials showed +10-800% YoY boosts from deals, 6 declined >10%), margin pressures (Urban One EBITDA -38%, Bank7 NIM -17bps), but positive guidance in industrials (Andersen +14-15% rev FY26, Phoenix 15.5-16.8M Boe). Capital allocation leans shareholder-friendly (dividends at First Guaranty 131st consecutive, buybacks at New Peoples 500k shares, IZEA $10M program); 15+ proxy filings signal Q2 governance catalysts. Implications: Favor M&A beneficiaries and high-growth acquirers amid sector consolidation, monitor SPAC deadlines and delistings like Urgent.ly.

30 high priority 20 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 17, 2026

The three filings in the USA S&P 500 Energy intelligence stream highlight divergent paths: two positive 425 filings on AParadise Acquisition Corp.'s $1.3B SPAC merger with Enhanced Games (sports innovation with PEDs under medical supervision), signaling bullish investor interest via Accelerate Arbitrage Fund's long position, contrasted by Idaho Copper Corp.'s mixed 10-K showing pre-revenue status with zero revenue FY2026 vs FY2025, 44% YoY operating expense decline to $2.6M, and 40% net loss improvement to $3.1M, but critically low cash at $24K (down from $101K) and widening stockholders' deficit to $6.5M. Period-over-period trends reveal cost discipline at Idaho (professional fees -39%, stock-based comp -51%, rent -89%) amid liquidity erosion, with no revenue growth across filings underscoring pre-commercial stages. Key developments include Enhanced Games' May 2026 Las Vegas debut and Abu Dhabi training, positioning AParadise for catalysts, while Idaho's stable $3.13M bond liabilities and $2.31M accrued interest flag balance sheet risks. Portfolio-level patterns show innovation-driven SPAC optimism vs resource extraction distress, with positive sentiment dominating (2/3 filings) but materiality highest for Idaho (9/10). Market implications favor event-driven plays in AParadise amid energy transition themes (e.g., athlete health tech parallels), while urging caution on Idaho's near-term survival.

3 high priority 3 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 17, 2026

Across 50 diverse SEC filings (despite Financials stream focus, including banks, asset managers, SPACs, industrials, biotech), overarching themes include robust M&A/SPAC activity (e.g., Victory Capital's improved Janus Henderson bid, bank mergers like UBFO/CWBC), mixed revenue growth with outliers like Energy Vault's 340% YoY surge and Mechanics Bancorp's 817% net income jump post-merger, but persistent margin pressures and widening losses in media/retail (Urban One -16.5% YoY rev). Period-over-period trends show 12/25 reporting companies with revenue growth averaging +45% YoY where positive, but 8/20 with margin compression (avg -150bps, e.g., Xerox -440bps gross), and Adjusted EBITDA improvements in 7 cases (e.g., Citi Trends +$26M FY YoY). Financials subset (Mechanics, Bank7, Victory, T Rowe, TWO Harbors) highlights asset/deposit growth (+36% YoY) and accretive deals, offset by NIM declines (-12bps to -117bps). Critical developments: regulatory approvals advancing bank mergers (Q2 2026 closes), SPAC extensions/mergers, and positive guidance (Energy Vault 30% 2026 rev growth). Portfolio implications: overweight growing financial consolidators, monitor SPAC redemptions/deadlines for dilution risks, favor revenue accelerators amid macro uncertainty.

34 high priority 16 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 17, 2026

Across 50 8-K filings from March 17, 2026, dominant themes include widespread executive and board changes (28 instances, with 18 positive appointments/promotions outweighing 10 neutral retirements/resignations), aggressive financing via convertible notes/debt (e.g., $4.3M Tenon, $500M Indivior, $124K American Rebel), and key M&A/contract wins (Fulgent $56.9M acquisition, Duos $176M GPUaaS over 36 months). Period-over-period data is sparse but highlights Bicycle Therapeutics' Q4 revenue surge +$44.3M YoY (to $48M) and FY +$37.3M (to $72.6M), offset by FY net loss widening to $219M (+$50M YoY) from R&D; no broad margin compression but dilution risks in 8 small-cap debt deals. Capital allocation shines with First Industrial's $250M open-ended buyback and Beazer Homes' 44% credit facility expansion to $525M. Sector patterns favor biotech/health (positive sentiment in 6/7 filings) and infrastructure (Duos, DTE/Google deals), signaling management conviction via experienced hires amid liquidity maneuvers. Implications: Bullish for growth-stage firms securing capital/contracts, cautious on dilution-heavy financings; portfolio tilt toward health/tech with catalysts like Duos' 75MW expansion and Clene's NIH-funded ALS program through Aug 2026.

50 high priority 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 17, 2026

Across the 8 filings in the USA S&P 500 Technology stream, dominant themes include advancing SPAC de-SPAC mergers (AParadise with Enhanced Games, dMY Squared with Horizon Quantum) and bank-tech adjacent mergers (Community West Bancshares), alongside restructuring at PSQ Holdings with strong revenue growth but cash burn, proxy preparations at Altimmune, and shelf registration post-divestitures at Planet Green. Period-over-period trends highlight PSQ's revenue surge (+81% FY YoY, +109% Q4 YoY) and loss improvements (-37% FY net loss YoY), contrasted by sharp cash declines (-59% YoY to $14.6M) and equity drops (-50% to $13.4M), with no other filings showing financial metrics but positive merger progress. Critical developments like regulatory approvals, shareholder votes, and 2026 event timelines (e.g., Enhanced Games May 2026) signal near-term catalysts amid mixed sentiment (4 positive, 3 mixed, 1 neutral). Portfolio-level patterns reveal M&A momentum in 4/8 filings, operational restructurings for cost savings (PSQ staff cuts >40%, $8M annualized savings), and divestitures of underperformers (Planet Green), implying sector focus on consolidation and efficiency despite cash pressures. Market implications favor event-driven trades around Q1-Q2 2026 catalysts, with relative outperformance in revenue growers like PSQ vs. stagnant peers.

4 high priority 4 medium 8 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 17, 2026

Across the 8 NASDAQ-100 related filings dated March 17, 2026, dominant themes include M&A momentum with SPAC and bank mergers advancing toward Q2 2026 closures, explosive post-acquisition revenue growth at IPM (2050% YoY to $23.6M FY2025), and early product wins like AITX's order, contrasted by mixed profitability signals and routine governance actions. Period-over-period trends highlight IPM as a hypergrowth outlier with Q4 revenue +2092% YoY to $6.1M but -1.7% QoQ decline, net losses improving 77% YoY to $2.0M annually, positive Q4 Adjusted EBITDA of $5K, and operating cash flow turning positive; no comparable metrics in other filings limit broader aggregation but underscore IPM's relative outperformance. Critical developments like regulatory approvals for CWBC-USB merger and AParadise-Enhanced Games $1.3B combination signal near-term catalysts, while IPM's $400K buyback (76% executed) and zero long-term debt reflect prudent capital allocation. Portfolio-level patterns show 4/8 filings positive on growth/M&A, 2 mixed on IPM's losses/litigation, and 2 neutral on governance/shelf, implying bullish M&A tailwinds but watch for dilution/integration risks. Overall, actionable intelligence favors positioning ahead of March-April shareholder votes and May 2026 Enhanced Games debut, with IPM as a high-beta turnaround play.

4 high priority 4 medium 8 total filings